Deepen mechanistic insight into VEGF×PD-1, sharpen target selectivity, and optimize binding affinity to accelerate bispecific discovery in oncology and autoimmune indications.
Unpack the latest in VEGF×PD-1 biology, target pairing, and binding optimization to drive next-gen bispecifics. With ivonescimab showing a 49% PFS gain in NSCLC, momentum is building. As bispecifics expand into autoimmune and TCEs, the 16th World Bispecific Summit offers real-world insights to overcome translational hurdles and accelerate smarter, safer therapeutic design.
View Event
